Brand | Product data | Purity | Price range | Estimated delivery |
---|---|---|---|---|
![]() | N-Boc-3-azacycloheptan-1-one REF: IN-DA0035CNCAS: 870842-23-2 | 98% | To inquire | Mon 03 Mar 25 |
![]() | Azepan-3-one, N-BOC protected REF: 54-OR301179CAS: 870842-23-2 | 97% | 113.00 € | Tue 04 Mar 25 |
![]() | 1-Boc-3-Oxoazepane REF: 10-F046903CAS: 870842-23-2 | 98.0% | 35.00 €~1,073.00 € | Thu 06 Mar 25 |
![]() | tert-Butyl 3-oxoazepane-1-carboxylate REF: 3D-FB156451CAS: 870842-23-2 | Min. 95% | - - - | Discontinued product |
![discount label](https://static.cymitquimica.com/public/img/discount.png)
N-Boc-3-azacycloheptan-1-one
CAS:870842-23-2
Formula:
C11H19NO3
Purity:
98%
Color and Shape:
Liquid
Molecular weight:
213.2735
Ref: IN-DA0035CN
1g | 63.00 € | ||
5g | 183.00 € | ||
10g | 219.00 € | ||
25g | 600.00 € | ||
50g | To inquire | ||
100mg | 27.00 € | ||
250mg | 47.00 € |
Estimated delivery in United States, on Monday 3 Mar 2025
![discount label](https://static.cymitquimica.com/public/img/discount.png)
Azepan-3-one, N-BOC protected
CAS:870842-23-2
Purity:
97%
Color and Shape:
Colourless Oil
Molecular weight:
213.27g/mol
Ref: 54-OR301179
1g | 113.00 € |
Estimated delivery in United States, on Tuesday 4 Mar 2025
![discount label](https://static.cymitquimica.com/public/img/discount.png)
1-Boc-3-Oxoazepane
CAS:870842-23-2
Purity:
98.0%
Color and Shape:
Liquid
Molecular weight:
213.27699279785156
Ref: 10-F046903
1g | 56.00 € | ||
5g | 180.00 € | ||
10g | 288.00 € | ||
25g | 545.00 € | ||
50g | 1,073.00 € | ||
250mg | 35.00 € |
Estimated delivery in United States, on Thursday 6 Mar 2025
![discount label](https://static.cymitquimica.com/public/img/discount.png)
tert-Butyl 3-oxoazepane-1-carboxylate
CAS:870842-23-2
tert-Butyl 3-oxoazepane-1-carboxylate is a chiral compound with two stereoisomers. It is an asymmetric synthesis that …
Formula:
C11H19NO3
Purity:
Min. 95%
Molecular weight:
213.27 g/mol
Ref: 3D-FB156451
100mg | Discontinued | Request information | |
250mg | Discontinued | Request information | |
500mg | Discontinued | Request information |